[go: up one dir, main page]

MX2009009787A - Mutaciones de k-ras y terapia con anticuerpos anti-egfr. - Google Patents

Mutaciones de k-ras y terapia con anticuerpos anti-egfr.

Info

Publication number
MX2009009787A
MX2009009787A MX2009009787A MX2009009787A MX2009009787A MX 2009009787 A MX2009009787 A MX 2009009787A MX 2009009787 A MX2009009787 A MX 2009009787A MX 2009009787 A MX2009009787 A MX 2009009787A MX 2009009787 A MX2009009787 A MX 2009009787A
Authority
MX
Mexico
Prior art keywords
ras mutations
egfr antibody
antibody therapy
methods
ras
Prior art date
Application number
MX2009009787A
Other languages
English (en)
Inventor
Todd Juan
Daniel Freeman
Robert Radinsky
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39689242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009787(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2009009787A publication Critical patent/MX2009009787A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a mutaciones de K-ras, a polinucleótidos que codifican polipéptidos de K-ras mutantes, y a métodos para identificar mutaciones de K-ras. La presente invención también se refiere a métodos para diagnosticar cáncer; y métodos y kits para pronosticar la utilidad de los agentes de unión específica anti-EGFr en el tratamiento de tumores.
MX2009009787A 2007-03-13 2008-03-11 Mutaciones de k-ras y terapia con anticuerpos anti-egfr. MX2009009787A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90694307P 2007-03-13 2007-03-13
PCT/US2008/003312 WO2008112269A2 (en) 2007-03-13 2008-03-11 K-ras mutations and anti-egfr antibody therapy

Publications (1)

Publication Number Publication Date
MX2009009787A true MX2009009787A (es) 2009-09-22

Family

ID=39689242

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009787A MX2009009787A (es) 2007-03-13 2008-03-11 Mutaciones de k-ras y terapia con anticuerpos anti-egfr.

Country Status (21)

Country Link
US (3) US20080293055A1 (es)
EP (2) EP2465950B1 (es)
JP (1) JP2010521153A (es)
AR (1) AR065687A1 (es)
AU (1) AU2008226803A1 (es)
CA (1) CA2680326A1 (es)
CL (1) CL2008000717A1 (es)
CY (2) CY1115333T1 (es)
DK (2) DK2121989T4 (es)
ES (2) ES2635051T3 (es)
HR (2) HRP20140360T4 (es)
HU (1) HUE033695T2 (es)
LT (1) LT2465950T (es)
MX (1) MX2009009787A (es)
PE (1) PE20081880A1 (es)
PL (2) PL2121989T5 (es)
PT (2) PT2121989E (es)
RS (2) RS56422B1 (es)
SI (2) SI2465950T1 (es)
TW (1) TW200902553A (es)
WO (1) WO2008112269A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2370054T3 (es) * 2005-08-24 2011-12-12 Bristol-Myers Squibb Company Biomarcadores y procedimientos para determinar la sensibilidad a moduladores del receptor del factor de crecimiento epidérmico.
AU2007253740A1 (en) 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
AR065686A1 (es) * 2007-03-13 2009-06-24 Amgen Inc Mutaciones de k- ras y b- raf y terapia con anticuerpos anti- egfr
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
US8502015B1 (en) 2009-07-06 2013-08-06 Transgenex Nanobiotech, Inc. Method of inducing cancer
CN102115782B (zh) * 2009-12-30 2014-06-18 北京雅康博生物科技有限公司 用于定量检测K-ras突变的试剂盒
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
WO2011130265A2 (en) * 2010-04-12 2011-10-20 Response Genetics, Inc. Kras primers and probes
RU2565550C2 (ru) 2010-09-24 2015-10-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Прямой захват, амплификация и секвенирование днк-мишени с использованием иммобилизированных праймеров
WO2012138997A1 (en) 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
CA2855356A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
PT2893040T (pt) 2012-09-04 2019-04-01 Guardant Health Inc Métodos para deteção de mutações raras e de variação do número de cópias
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
CN105074009B (zh) * 2013-03-19 2017-09-26 凸版印刷株式会社 Egfr抑制剂的敏感性的预测方法
CN106062214B (zh) 2013-12-28 2020-06-09 夸登特健康公司 用于检测遗传变异的方法和系统
ES2844229T3 (es) 2014-05-13 2021-07-21 Univ Texas Mutaciones génicas y alteraciones en el número de copias de EGFR, KRAS y MET
WO2017106768A1 (en) 2015-12-17 2017-06-22 Guardant Health, Inc. Methods to determine tumor gene copy number by analysis of cell-free dna
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
CN110357965A (zh) * 2019-06-24 2019-10-22 浙江大学 一种突变型kras特异性抗体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5470705A (en) 1992-04-03 1995-11-28 Applied Biosystems, Inc. Probe composition containing a binding domain and polymer chain and methods of use
JP2775346B2 (ja) 1992-04-03 1998-07-16 アプライド バイオシステムズ，インコーポレイテッド プローブ構成物および方法
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP3628614B2 (ja) 1999-03-15 2005-03-16 アプレラ コーポレイション 多重核酸検出のためのプローブ／移動度モディファイア複合体
AU2001265121A1 (en) 2000-05-30 2001-12-11 Applera Corporation Methods for detecting target nucleic acids using coupled ligation and amplification
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
CA2485691A1 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
EP1636380A2 (en) 2003-05-30 2006-03-22 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
CN104774931B (zh) 2004-03-31 2017-11-10 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
US7932026B2 (en) * 2004-06-04 2011-04-26 Genentech, Inc. EGFR mutations
WO2006047481A2 (en) * 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Enhanced amplifiability of minute fixative-treated tissue samples, minute stained cytology samples, and other minute sources of dna
CN102007220A (zh) 2005-04-01 2011-04-06 安姆根有限公司 表皮生长因子受体基因拷贝数
US20090269344A1 (en) * 2005-04-14 2009-10-29 Salvatore Siena Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
ES2398709T5 (es) 2005-06-28 2017-04-18 Genentech, Inc. Mutaciones en EGFR y KRAS para predecir la respuesta de un paciente al tratamiento con inhibidores de EGFR
WO2007011702A2 (en) * 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Use of egfr inhibitors to prevent or treat obesity
ES2370054T3 (es) 2005-08-24 2011-12-12 Bristol-Myers Squibb Company Biomarcadores y procedimientos para determinar la sensibilidad a moduladores del receptor del factor de crecimiento epidérmico.
WO2007109571A2 (en) * 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US8293501B2 (en) * 2006-09-12 2012-10-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for performing low background multiplex nucleic acid amplification reactions
AR065686A1 (es) * 2007-03-13 2009-06-24 Amgen Inc Mutaciones de k- ras y b- raf y terapia con anticuerpos anti- egfr

Also Published As

Publication number Publication date
HRP20140360T1 (hr) 2014-05-23
SI2121989T2 (sl) 2022-05-31
EP2121989B2 (en) 2022-03-09
SI2465950T1 (sl) 2017-11-30
US20120264129A1 (en) 2012-10-18
DK2121989T4 (da) 2022-06-20
CL2008000717A1 (es) 2008-09-22
AU2008226803A1 (en) 2008-09-18
DK2465950T3 (en) 2017-10-09
US20080293055A1 (en) 2008-11-27
PE20081880A1 (es) 2008-12-31
ES2635051T3 (es) 2017-10-02
HRP20140360T4 (hr) 2022-06-10
EP2465950A3 (en) 2013-03-13
AR065687A1 (es) 2009-06-24
PL2121989T3 (pl) 2014-07-31
ES2458626T3 (es) 2014-05-06
WO2008112269A3 (en) 2008-11-20
US20190048423A1 (en) 2019-02-14
TW200902553A (en) 2009-01-16
HRP20171509T1 (hr) 2017-11-17
DK2121989T3 (da) 2014-04-28
EP2465950B1 (en) 2017-07-12
SI2121989T1 (sl) 2014-06-30
US10030270B2 (en) 2018-07-24
EP2121989A2 (en) 2009-11-25
PL2465950T3 (pl) 2017-12-29
EP2121989B1 (en) 2014-01-22
PT2465950T (pt) 2017-10-17
US11155876B2 (en) 2021-10-26
ES2458626T5 (es) 2022-04-29
EP2465950A2 (en) 2012-06-20
WO2008112269A2 (en) 2008-09-18
RS56422B1 (sr) 2018-01-31
PT2121989E (pt) 2014-04-30
LT2465950T (lt) 2017-10-10
CY1119112T1 (el) 2018-02-14
RS53265B2 (sr) 2022-06-30
JP2010521153A (ja) 2010-06-24
CY1115333T1 (el) 2017-01-04
CA2680326A1 (en) 2008-09-18
PL2121989T5 (pl) 2023-03-06
RS53265B (sr) 2014-08-29
HUE033695T2 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
MX2009009787A (es) Mutaciones de k-ras y terapia con anticuerpos anti-egfr.
MX2009009779A (es) Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr.
WO2007103770A3 (en) Compositions and methods for analyzing renal cancer
TW200806322A (en) Diagnostics and treatments for tumors
IL243812A0 (en) Compounds of diarylhydantoin
WO2008097466A3 (en) Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors
ZA200709780B (en) Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
UA95068C2 (uk) Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
SG170080A1 (en) Human monoclonal antibodies to o8e
SG170728A1 (en) Anti-tumor cell antigen antibody therapeutics
WO2014081944A9 (en) Egfr and c-met-fibronectin type iii domain binding molecules
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
MX2009013410A (es) Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta.
MY161200A (en) Human cytomegalovirus neutralising antibodies and use thereof
WO2009015284A3 (en) Il-18 receptor antigen binding proteins
TN2011000524A1 (en) Antibodies specific to cadherin -17
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
UA102891C2 (uk) Повні людські антитіла, специфічні до cadm1
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18
MXPA05008794A (es) Antigeno de glicoproteina sima135 expresado en celulas tumorales humanas metastasicas.
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2005033133A3 (en) Polynucleotides encoding erbb-2 polypeptides and kits and methods using same
SG157321A1 (en) Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits

Legal Events

Date Code Title Description
FG Grant or registration